Cisplatin versus cetuximab given concurrently with definitive radiation therapy for locally advanced head and neck squamous cell carcinoma

Oncology (Switzerland)

Volumn 85, Issue 5, 2013, Pages 290-296

  Ley, Jessica ^a   Mehan, Paul ^a   Wildes, Tanya M ^a,b   Thorstad, Wade ^a,b   Gay, Hiram A ^a,b   Michel, Loren ^a,b   Nussenbaum, Brian ^a,b   Trinkaus, Kathryn ^a   Adkins, Douglas ^a,b  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MO   (United States)

Author keywords

Cetuximab; Cisplatin; Head and neck; Neoplasms; Radiation

Indexed keywords

CETUXIMAB; CISPLATIN;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLASSIFICATION; CLINICAL ARTICLE; CONFIDENCE INTERVAL; FEMALE; FOLLOW UP; HAZARD RATIO; HEAD AND NECK CARCINOMA; HUMAN; MALE; MEDICAL RECORD REVIEW; MIDDLE AGED; MUCOSA INFLAMMATION; OBSERVATION; PRIORITY JOURNAL; PROPENSITY SCORE; RECURRENT DISEASE; RETROSPECTIVE STUDY; SMOKING; SQUAMOUS CELL CARCINOMA; WART VIRUS; WEIGHT REDUCTION;

EID: 84889817966     PISSN: 00302414     EISSN: 14230232     Source Type: Journal    
DOI: 10.1159/000355194     Document Type: Article

References (19)

1. Parkin DM, Bray F, Ferlay J, Pisani P: Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74-108.
2. Pignon JP, le Maitre A, Maillard E, Bourhis J, MACH-NC Collaborative Group: Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. Radiother Onco 2009; 92: 4-14.
3. Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB, Jones CU, Sur R, Raben D, Jassem J, Ove R, Kies MS, Baselga J, Youssoufian H, Amellal N, Rowinsky EK, Ang KK: Radiotherapy plus cetuximab for squamouscell carcinoma of the head and neck. N Engl J Med 2006; 354: 567-578.
4. Bonner JA, Harari PM, Giralt J, Cohen RB, Jones CU, Sur RK, Raben D, Baselga J, Spencer SA, Zhu J, Youssoufian H, Rowinsky EK, Ang KK: Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol 2010; 11: 21-28.
5. Piccirillo JF, Creech C, Zequeira R, Anderson S, Johnston AS: Inclusion of comorbidity into oncology data registries. J Registry Manag 1999; 26: 66-70.
6. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A: AJCC Cancer Staging Manual, ed 7. New York, Springer, 2010.
7. Chernock RD, El-Mofty SK, Thorstad WL, Parvin CA, Lewis JS: HPV-related nonkeratinizing squamous cell carcinoma of the oropharynx: utility of microscopic features in predicting patient outcome. Head Neck Pathol 2009; 3: 186-194.
8. Forastiere AA, Goepfert H, Maor M, Pajak TF, Weber R, Morrison W, Glisson B, Trotti A, Ridge JA, Chao C, Peters G, Lee DJ, Leaf A, Ensley J, Cooper J: Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med 2003; 349: 2091-2098.
9. Caudell JJ, Sawrie SM, Spencer SA, Desmond RA, Carroll WR, Peters GE, Nabell LM, Meredith RF, Bonner JA: Locoregionally advanced head and neck cancer treated with primiary radiotherapy: a comparison of the addition of cetuximab or chemotherapy and the impact of protocol treatment. Int J Rad Oncol Biol Phys 2008; 71: 676-681.
10. Koutcher L, Sherman E, Fury M, Wolden S, Zhang Z, Mo Q, Stewart L, Schupak K, Gelblum D, Wong R, Kraus D, Shah J, Zelefsky M, Pfister D, Lee N: Concurrent cisplatin and radiation versus cetuximab and radiation for locally advanced head-and-neck cancer. Int J Rad Oncol Biol Phys 2011; 81: 915-922.
11. Kumar B, Cordell KG, Lee JS, Worden FP, Prince ME, Tran HH, Wolf GT, Urba SG, Chepeha DB, Teknos TN, Eisbruch A, Tsien CI, Taylor JM, D'Silva NJ, Yang K, Kurnit DM, Bauer JA, Bradford CR, Carey TE: EGFR, p16, HPV titer, Bcl-xL and p53, sex, and smoking as indicators of response to therapy and survival in oropharyngeal cancer. J Clin Oncol 2008; 26: 3128-3137.
12. Kong CS, Narasimhan B, Cao H, Kwok S, Erickson JP, Koong A, Pourmand N, Le QT: The relationship between human papillomavirus status and other molecular prognostic markers in head & neck squamous cell carcinomas. Int J Rad Oncol Biol Phys 2009; 74: 553-561.
13. Al-Swiahb JN, Huang CC, Fang FM, Chuang HC, Huang HY, Luo SD, Chen CH, Chen CM, Chien CY: Prognostic impact of p16, p53, epidermal growth factor receptor, and human papillomavirus in oropharyngeal cancer in a betel nut-chewing area. Arch Otolaryngol Head Neck Surg 2010; 136: 502-508.
14. Hong A, Dobbins T, Lee CS, Jones D, Jackson E, Clark J, Armstrong B, Harnett G, Milross C, O'Brien C, Rose B: Relationships between epidermal growth factor receptor expression and human papillomavirus status as markers of prognosis in oropharyngeal cancer. Eur J Cancer 2010; 46: 2088-2096.
15. Perrone F, Suardi S, Pastore E, Casieri P, Orsenigo M, Caramuta S, Dagrada G, Losa M, Licitra L, Bossi P, Staurengo S, Oggionni M, Locati L, Cantu G, Squadrelli M, Carbone A, Pierotti MA, Pilotti S: Molecular and cytogenetic subgroups of oropharyngeal squamous cell carcinoma. Clin Cancer Res 2006; 12: 6643-6651.
16. Reimers N, Kasper HU, Weissenborn SJ, Stutzer H, Preuss SF, Hoffmann TK, Speel EJ, Dienes HP, Pfister HJ, Guntinas-Lichius O, Klussmann JP: Combined analysis of HPVDNA, p16 and EGFR expression to predict prognosis in oropharyngeal cancer. Int J Cancer 2007; 120: 1731-1738.
17. Cohen EEW: Role of epidermal growth factor receptor pathway-targeted therapy in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol 2006; 24: 2659-2665.
18. Vermorken J, Stohlmacher J, Oliner K, et al: Safety and efficacy of panitumumab in HPV positive and HPV negative recurrent/metastatic squamous cell carcinoma of the head and neck: analysis of the phase 3 SPECTRUM trial. Abstract 25LBA, 2011 European Multidisciplinary Cancer Congress.
19. Ang KK, Zhang QE, Rosenthal DI, Nguyen-Tan P, Sherman EJ, Weber RS, Galvin JM, Schwartz DL, El-Naggar AK, Gillison ML, Jordan R, List MA, Konski AA, Thorstad WL, Trotti A, Beitler JJ, Garden AS, Spanos WJ, Yom SS, Axelrod RS: A randomized phase III trial (RTOG 0522) of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III-IV head and neck squamous cell carcinomas (HNC). J Clin Oncol 2011; 29(suppl):abstract 5500.